This article only represents the author's own views.
The battle is on to develop innovative drugs to tackle a global obesity crisis, including pills to control blood sugar levels and curb hunger pangs.
Drugs giant AstraZeneca (AZN.LON) is investing heavily in becoming a major player in the weight-loss market after sealing a deal worth up to $2 billion for rights to an oral obesity drug being developed by China’s Eccogene Inc..
您已閱讀7%（428字），剩余93%（5801字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。